iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Lupin claims to have acquired the trademarks Ondero and Ondero Met from Boehringer Ingelheim

21 Aug 2023 , 10:11 AM

Lupin announced on Friday that it has purchased the trademark rights for the diabetes medications Ondero (linagliptin) and Ondero Met (linagliptin and metformin) from Boehringer Ingelheim for 26 million euros (Rs 235 crore) in an all-cash transaction.

Ondero and Ondero Met’s most recent sales were not disclosed by Lupin, however, the company did state that the acquisition was anticipated to add value to its range of diabetes medications.

As part of a co-marketing agreement with Boehringer Ingelheim India, Lupin has been promoting Ondero and Ondero Met in the Indian market since 2015.

As a global leader in the anti-diabetes market, Lupin further cemented its position with the acquisition of Ondero and Ondero Met, according to Nilesh Gupta, MD. ‘With the acquisition of Ondero and Ondero Met, we continue to offer a wide portfolio of products to enable access to medication for patients.’

For feedback and suggestions, write to us at editorial@iifl.com

Lupin Limited - Wikipedia

Related Tags

  • Diebetes
  • Lupin
  • Ondero
  • Ondero Met
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.